Brennan Cronquist

CIO2022 Highlights

Irreversible Electroporation vs Radiofrequency Ablation for HCC

10/27/2022

B. Cronquist, 4th year medical student at the George Washington University School of Medicine and Health Sciences, discusses his CIO2022 abstract, "CIO 2022-6 Irreversible Electroporation versus Radiofrequency Ablation as a Treatment Option...

B. Cronquist, 4th year medical...

10/27/2022

IO Learning

CIO 2022-6 Irreversible Electroporation versus Radiofrequency Ablation as a Treatment Option in Hepatocellular Carcinoma

Purpose: In the United States, hepatocellular carcinoma (HCC) has an incidence of 7.7 per 100,000, which has steadily increased from 1992, when there was an incidence of 4.1 per 100,000. ...

D. Scher ;

Brennan Cronquist ;

10/18/2022

CIO 2022-7 Irreversible Electroporation versus Microwave Ablation as a Treatment Option in Hepatocellular Carcinoma

Purpose: In the United States, hepatocellular carcinoma (HCC) has an incidence of 7.7 per 100,000 and is the most common cause of primary liver cancer worldwide. The gold-standard treatme...

Brennan Cronquist ;

D. Scher ;

10/18/2022